Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Wise Policy" Needed To Link Comparative Effectiveness with Individualized Medicine

This article was originally published in RPM Report

Executive Summary

As comparative effectiveness matures from a political rallying cry and budget strategy to a process that the medical community will have to face as a new force with more financial and public support, the most thoughtful people in medicine are trying to find a way to understand the term and how it fits into other trends. It's not easy, even for them.

You may also be interested in...



A Case Study in Regulatory Innovation: Pharmacogenomics at FDA

FDA’s idea to encourage “voluntary” submission of pharmacogenomic data started slow—but the program has paid significant dividends for the agency. In addition to building knowledge and advancing the use of PKG in drug regulation, it has also won over industry and become a case study to support broader funding of regulatory science.

NIH Director Nominee Collins May Push Translational Medicine Into Spotlight

Francis Collins' intellectual agility and experience working on huge initiatives with a lot of moving parts - the human genome project comes to mind - will serve him well as the National Institutes of Health's director

The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness

Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel